Sector: Biotech
Platform: StartEngine
Valuation: $25 million
Minimum Investment: $500
🧩 What They Do
Pioneering 3D bioprinting technology aimed at curing Type 1 Diabetes.
📈 Why It Might Be the Next Big Thing
3D bioprinting is a frontier in medicine
Focus on Type 1 Diabetes provides a clear market
Success could lead to a groundbreaking treatment
💰 Who’s Backing Them
Notable Investors: ✅ Hackensack Meridian Health
📌 Snapshot
⭐ Notable Backers: ✅
💵 Min. Investment: $500
📊 Growth Signal: Working on breakthrough technology
🧠 Founder Cred: Not provided
🔎 My Take
This is for moonshot investors—high science, high risk, potentially revolutionary.
📖 Disclaimer: This newsletter is for informational purposes only and does not constitute financial advice or investment solicitation.